drug · enzyme
pegunigalsidase alfa
Phase 3updated 3mo agoby Chiesi Farmaceutici SpA🔗 ChEMBL
Phase 3community read0 votes
Enzyme drug with a maximum clinical stage of Approval, with an approval for fabry disease.
all catalysts(0)
nothing on the calendar yet
Trials studying pegunigalsidase alfa
- phase3Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
- —Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting
- phase3Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
- —Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients
- phase3Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks
- phase3Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
- phase2Extension Study of PRX-102 for up to 60 Months
- phase3Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that